Larkspur Biosciences kicks off with $30M+, hunting for new oncology immunotherapies
Based in Massachusetts, Larkspur Biosciences, a biotech focused on developing new immuno-oncology treatments, is now armed with $35.5 million in combined seed/Series A backing.
The round, led by the Polaris Innovation Fund, 3E Bioventures Capital and Takeda’s VC arm, will help fund development of new therapies for colorectal cancer.
Larkspur CEO Catherine Sabatos-Peyton, a former exec director at Novartis Institutes for BioMedical Research, has been running the company in stealth mode since November. She told Endpoints News that she got involved with Larkspur in 2021, originally as the chief science officer. Sabatos-Peyton did her PhD under the tutelage of Vijay Kuchroo, one of the co-founders of Larkspur, while at Harvard University studying autoimmunity.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters